Immunoassay Systems Evaluated for Detection of Antiphospholipid Antibodies
|
By LabMedica International staff writers Posted on 28 Mar 2016 |
|
Image: The Bio-Flash Rapid-Response Chemiluminescent Analyzer (Photo courtesy of Inova Diagnostics).
Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), or also Hughes syndrome, is an autoimmune, hypercoagulable state caused by antiphospholipid antibodies. APS provokes blood clots (thrombosis) in arteries and veins as well as pregnancy-related complications such as miscarriage, stillbirth, preterm delivery, and severe preeclampsia.
The diagnostic criteria require one clinical event, such as thrombosis or pregnancy complication, and two antibody blood tests spaced at least three months apart that confirm the presence of either lupus anticoagulant, or anti-β2-glycoprotein-I (since β2-glycoprotein-I (GpI) antibodies are a subset of anti-cardiolipin antibodies (aCL), an anti-cardiolipin assay can be performed as a less specific proxy.
Scientists at the Hospital Ordine Mauriziano (Torino, Italy) assayed aCL and a-β2GpI in serum samples from 30 healthy individuals, 77 patients with antiphospholipid syndrome (APS) diagnosed according to the Sydney criteria, 51 patients with autoimmune diseases, eight patients with previous thrombotic events, six patients with other diseases, and 18 patients with infectious diseases.
The investigators used the enzyme-linked immunosorbent assay (ELISA, Inova Diagnostics; San Diego, CA, USA); enzyme immunoassays (EliA) (Phadia Laboratory Systems; Freiburg im Breisgau, Germany); chemiluminescence enzyme immunoassay (CliA), (Zenit-RA, A.Menarini Diagnostics; Florence, Italy); and Inova Diagnostics’ CliA Bio-Flash to evaluate analytical and clinical performances of IgG and IgM anticardiolipin (aCL) antibodies and anti-β2-glycoprotein I (a-β2GpI) antibodies and upper limit reference ranges (99th percentiles) in comparison with manufacturer's cutoff values with different commercial methods.
The team found that anticardiolipin and a-β2GpI immunoglobulin G (IgG) and IgM immunoassays showed good analytic performances with both 99th percentile and manufacturer's cutoff reference values. Their results showed fair to moderate agreement among assays. In-house cutoff values gave significantly better performances only for a-β2GpI IgG with all the immunoassays analyzed with the exception of Inova CliA Bio-Flash where they obtained the same performances with in-house and manufacturer's cutoffs.
The authors concluded that by guidelines, all laboratories are strongly advised to validate/verify the manufacturer's cutoff values. They recommended establishing low-positive, medium-/high-positive, and high-positive CliA IgG aCL and a-β2GpI ranges in order to help clinicians in the diagnosis and treatment of APS. The study was published on March 15, 2016, in the International Journal of Laboratory Hematology.
Related Links:
Hospital Ordine Mauriziano
Inova Diagnostics
Phadia Laboratory Systems
The diagnostic criteria require one clinical event, such as thrombosis or pregnancy complication, and two antibody blood tests spaced at least three months apart that confirm the presence of either lupus anticoagulant, or anti-β2-glycoprotein-I (since β2-glycoprotein-I (GpI) antibodies are a subset of anti-cardiolipin antibodies (aCL), an anti-cardiolipin assay can be performed as a less specific proxy.
Scientists at the Hospital Ordine Mauriziano (Torino, Italy) assayed aCL and a-β2GpI in serum samples from 30 healthy individuals, 77 patients with antiphospholipid syndrome (APS) diagnosed according to the Sydney criteria, 51 patients with autoimmune diseases, eight patients with previous thrombotic events, six patients with other diseases, and 18 patients with infectious diseases.
The investigators used the enzyme-linked immunosorbent assay (ELISA, Inova Diagnostics; San Diego, CA, USA); enzyme immunoassays (EliA) (Phadia Laboratory Systems; Freiburg im Breisgau, Germany); chemiluminescence enzyme immunoassay (CliA), (Zenit-RA, A.Menarini Diagnostics; Florence, Italy); and Inova Diagnostics’ CliA Bio-Flash to evaluate analytical and clinical performances of IgG and IgM anticardiolipin (aCL) antibodies and anti-β2-glycoprotein I (a-β2GpI) antibodies and upper limit reference ranges (99th percentiles) in comparison with manufacturer's cutoff values with different commercial methods.
The team found that anticardiolipin and a-β2GpI immunoglobulin G (IgG) and IgM immunoassays showed good analytic performances with both 99th percentile and manufacturer's cutoff reference values. Their results showed fair to moderate agreement among assays. In-house cutoff values gave significantly better performances only for a-β2GpI IgG with all the immunoassays analyzed with the exception of Inova CliA Bio-Flash where they obtained the same performances with in-house and manufacturer's cutoffs.
The authors concluded that by guidelines, all laboratories are strongly advised to validate/verify the manufacturer's cutoff values. They recommended establishing low-positive, medium-/high-positive, and high-positive CliA IgG aCL and a-β2GpI ranges in order to help clinicians in the diagnosis and treatment of APS. The study was published on March 15, 2016, in the International Journal of Laboratory Hematology.
Related Links:
Hospital Ordine Mauriziano
Inova Diagnostics
Phadia Laboratory Systems
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
H.pylori Test
Humasis H.pylori Card
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Molecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
Technology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
